Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3K ´ , and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.本發明公開了稠合雜環化合物、其製備方法、藥物組合物和用途。該稠合雜環化合物如式I、式II或式III所示。本發明的所述稠合雜環化合物及/或其藥學可接受的鹽的製備方法包括三條合成路線。本發明還提供了該稠合雜環化合物的藥物組合物，其含有如式I，式II，式III所示的稠合雜環化合物、其藥學上可接受的鹽、水合物、溶劑合物、多晶型物和其前驅藥中的一種或多種，及藥學上可接受的載體；並涉及該稠合雜環化合物及/或藥物組合物在製備激酶抑制劑中，以及製備用於防治與激酶有關的疾病的藥物中的應用。本發明的稠合雜環化合物對PI3Kδ具有選擇抑制作用，可用於製備防治癌症、感染、炎症或自身免疫性病變等細胞增殖類疾病的藥物。
